Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 3/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1327385 | 0.84 | CHRM1 (0.52) | CHRM1CHRM3CHRM2CHRM4HTR1A | |
| SCHEMBL829653 | 0.81 | L3MBTL1 (0.50) | L3MBTL1SIGMAR1 | |
| SCHEMBL11205736 | 0.79 | KEAP1 (0.48) | CHRM1SIGMAR1GNAO1 | |
| SCHEMBL17424057 | 0.79 | KEAP1 (0.48) | CHRM1SIGMAR1GNAO1 | |
| SCHEMBL5034030 | 0.78 | CHRM1 (0.49) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL1479904 | 0.78 | GNAI3 (0.50) | CHRM1L3MBTL1CHRM3CHRM2CHRM4 | |
| Bromide SCHEMBL5227189 | 0.76 | HTR4 (0.51) | CHRM1CHRM3CHRM2CHRM4HTR1A | |
| SCHEMBL7693845 | 0.76 | CHRM1 (0.48) | CHRM1L3MBTL1CHRM3CHRM2CHRM4 | |
| SCHEMBL5031515 | 0.76 | CHRM1 (0.47) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL24703548 | 0.76 | ALDH1A1 (0.44) | CHRM1L3MBTL1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1789049-A4 | CYCLIC AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1789049-A2 | CYCLIC AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006023617-A2 | CYCLIC AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | HCN4, CACNA1B, SCN5A | CHRM1 983/4885L3MBTL1 4594/4885CHRM3 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.